Randomised, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Lu AA24493 in Acute Ischemic Stroke.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Lu AA 24493 (Primary)
- Indications Stroke
- Focus Adverse reactions; Biomarker; Pharmacokinetics
- Sponsors Lundbeck A/S
- 31 Dec 2008 End date added from ClinicalTrials.gov.
- 31 Dec 2008 Status changed from active, no longer recruiting to completed, based on information from ClinicalTrials.gov.
- 19 Sep 2008 New source identified and integrated (ClinicalTrials.gov record).